DJIA: 16,502.80  -11.57 (-0.07%) | NASDAQ: 4,139.782  -21.675 (-0.52%) | S&P 500: 1,877.59  -1.96 (-0.10%) Markets close in 5 hrs 36 mins

  • Show Article Details

    Valeant Pharmaceuticals Inc won't pay whatever it takes to acquire rival Allergan Inc (AGN), and it will not turn its bid into an all-cash deal, Valeant Chief Executive Michael Pearson said on Tuesday in New York. Valeant and activist investor Bill Ackman made an unsolicited $47 billion bid to buy Botox maker Allergan (AGN) as it seeks to become one of the world's five biggest drug companies.

  • Show Article Details

    Valeant Pharmaceuticals (VRX) has lined up $15.5 billion in debt financing from Barclays and RBC Capital Markets to fund its proposed $47 billion purchase of Allergan Inc. (AGN), the company said on Tuesday in a press release. Valeant said that the committed financing would include secured bonds, unsecured bonds and bank debt.

  • Show Article Details

    HCA Holdings Inc (HCA) is among the bidders for Australian hospital operator Healthscope Ltd, which has put itself up for sale, the Sydney Morning Herald reported on Tuesday. HCA, the largest for-profit U.S. hospital operator, is competing against Malaysia's IHH, which is being advised by JPMorgan and CIMB, and at least one other potential Asian buyer, according to the report.

  • Show Article Details

    Shares of Omnicom Group (OMC) are down -1.99% to $70.07 after CEO John Wren said he was was unable to predict when its $35.1 billion merger with France's Publicis Groupe SA (PGPEF) would close. The deal reportedly hasn't won some key approvals. Yesterday, the advertising agency reported that 2014 first quarter revenue increased 3.0% to $3,502.2 million from $3,398.9 million in the first quarter of 2013.

  • Show Article Details

    By Danielle Robinson Allergan (AGN), the pharma giant behind Botox, saw its bonds plunge some 10 points Tuesday on news that activist investor William Ackman is leading an attempted hostile takeover of the company. Investors said that even an ultimately positive takeover would crush Allergan's A3/A+ investment-grade credit rating, and quickly jumped to market to sell off its paper.

  • Show Article Details

    * Netflix results lift Wall St, deal talk buoys Europe. * Threats of ECB action keeps euro subdued. * Oil prices fall on rising supplies. * U.S. bond prices slip before two-year supply. By Herbert Lash. Global equity markets rose on Tuesday, powered by solid U.S. corporate earnings and deal-making activity among European drugmakers, while the euro edged above break-even.

  • Show Article Details

    LONDON-- U.K. equities advanced Tuesday, with AstraZeneca PLC (AZN) gaining on speculation the British drug maker will receive a takeover bid, while GlaxoSmithKline PLC (GSK) shares rose as the pharmaceutical heavyweight made a couple of its own deals. U.K.' s FTSE 100 index leapt 0.9% to 6,681.76, the highest closing level since April 4, according to data from FactSet, following a four-day break in trading in observance of the Easter holiday. Last week, the index finished the holiday-shortened...

  • Show Article Details

     Lufthansa reiterated Tuesday that the new Oneworld hub in Charlotte won't be a problem for the Star Alliance co-founder, saying its passengers can continue to connect on US Airways."After negotiations with US Airways we are happy that the cooperation with US Airways on our Munich-Charlotte route will continue despite the fact that they are no longer with Star Alliance," said Lufthansa spokesma...

  • Show Article Details

    LONDON-- Drug makers took center stage in European trading Tuesday, with AstraZeneca PLC (AZN) shares posting their best advance in nearly three years on news of a potential takeover bid, and as GlaxoSmithKline PLC (GSK) climbed on the multibillion-dollar sales of a business unit. The Stoxx Europe 600 finished up 1.4% to 337.03 as investors returned from a four-day Easter holiday break to a slate of developments in the pharmaceutical sector, the best-performing group on the pan-European...

  • Show Article Details

    The battle against cancer has taken on a financial dimension, with Novartis (NVS)  agreeing to take a host of oncology drugs from GlaxoSmithKline  in the largest of four multi-billion transactions by the Swiss company, and Pfizer reportedly missing out in a run for AstraZeneca (AZN)  cancer treatments.

  • Show Article Details

    Valeant Pharmaceuticals International (VRX)  and activist investor Bill Ackman on Tuesday revealed the details of their combined hostile effort to acquire Botox-maker Allergan, a move that is the well-known insurgent's first hostile acquisition partnership and one that would bring together two mid-sized pharmaceutical companies if consummated.

  • Show Article Details

    * FTSEurofirst 300 up 1.4 pct, Euro STOXX 50 up 1.3 pct. * Indexes extend gains after strong euro zone consumer confidence. * AstraZeneca jumps 6.3 pct on M&A talk. * Philips drops 5.5 pct after disappointing earnings. By Francesco Canepa.